Details for Patent: 7,550,595
✉ Email this page to a colleague
Which drugs does patent 7,550,595 protect, and when does it expire?
Patent 7,550,595 protects YUPELRI and is included in one NDA.
This patent has thirty-eight patent family members in twenty-seven countries.
Summary for Patent: 7,550,595
| Title: | Biphenyl compounds useful as muscarinic receptor antagonists |
| Abstract: | This invention provides compounds of formula I: ##STR00001## wherein a, b, c, d, m, n, p, s, t, W, Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders. |
| Inventor(s): | Mammen; Mathai (Redwood Shores, CA), Ji; Yu-Hua (Redwood City, CA), Mu; YongQi (Los Altos, CA), Husfeld; Craig (Redwood City, CA), Li; Li (Sunnyvale, CA) |
| Assignee: | Theravance, Inc. (South San Francisco, CA) |
| Application Number: | 11/880,002 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Delivery; |
Drugs Protected by US Patent 7,550,595
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Ireland Ltd | YUPELRI | revefenacin | SOLUTION;INHALATION | 210598-001 | Nov 9, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
